New dialysis solution may delay need for full treatment in kidney patients
NCT ID NCT05721404
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This trial investigates whether using icodextrin, a special dialysis solution, can help people on peritoneal dialysis (a type of home dialysis for kidney failure) stay on a lower-dose regimen for longer. Participants are randomly assigned to receive either icodextrin or a standard sugar-based solution when they show signs of fluid overload. The goal is to see if icodextrin delays the need to switch to full-dose dialysis and improves outcomes like infection rates and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Icodextrin peritoneal dialysis solution
What this could lead to
If it works, this could help people on peritoneal dialysis maintain a lower treatment burden for longer, with less glucose exposure and potentially fewer complications.
What could go wrong
This is a single-center Phase 4 trial with 194 participants, so results may not apply broadly. The benefit may be modest, and icodextrin can cause side effects like skin reactions or sterile peritonitis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact